



MONDAY JUNE 4, 2012

4:00pm – 7:00pm Registration Open *Grand Ballroom Foyer*

TUESDAY JUNE 5, 2012

7:00am – 7:00pm Registration Open *Grand Ballroom Foyer*

8:00am – 5:30pm GLOBAL REGULATORY PERSPECTIVES WORKSHOP – *separate registration fee required* *Grand Ballroom B*

8:00am – 3:00pm FLOW CYTOMETRY WORKSHOP MAIN ROOM – *separate registration fee required* *Grand Ballroom D*

Grand Ballroom D *Willow A* *Willow B*
 CONCURRENT SESSIONS “A” CONCURRENT SESSIONS “B” CONCURRENT SESSIONS “C”

8:00am – 5:00pm FACT Training Workshop – *separate registration fee required* *Aspen Room*

FACT Training Breakout Session – *separate registration fee required* *Cedar B Room*

5:00pm – 7:00pm Corporate Symposium Hosted by Miltenyi Biotec (*Refer to Corporate Guide for details*) *Grand Ballroom C*

7:00pm – 7:30pm WELCOME ADDRESS *Grand Ballroom AB*

7:30pm – 9:30pm EXHIBITS OPEN AND WELCOME RECEPTION *Metropolitan Ballroom & Foyer, Ballard Room*

WEDNESDAY JUNE 6, 2012

7:00am – 4:00pm Registration Open *Grand Ballroom Foyer*

Corporate Tutorial Hosted by Owl biomedical (*Refer to Corporate Guide for details*) *Grand Ballroom A*

7:30am – 8:30am TECHNICAL SESSION 1 *Grand Ballroom B*

Imaging Cell Therapy
Chair: Rao Papineni (US)
Speakers:
 Rao Papineni (US) – *Multimodal Imaging in Cell Trafficking*
 Ali Arbab (US) – *Imaging administered stem cells by in vivo imaging modalities*

TECHNICAL SESSION 2 *Grand Ballroom C*

NK Expansion for Clinical Trials
Chair: Didier Blaise (FR)
Speakers:
 Didier Blaise (FR) – *Role of NK cells in allogeneic SCT and perspectives*
 Jeffrey Miller (US) – *How to educate NK cells to treat cancer*



7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 1
Best Practices in Cell Therapy Process Development

Grand Ballroom D

Chair: Jon Rowley (US)

Speakers:

Jon Rowley (US) – *Designing High Impact Cell Therapy Process Development Programs*

Andy Campbell (US) – *Media and Process Development for Cell Therapy Applications: Implications for Scale-up and Manufacturing*

Aby Mathew (US) – *Designing Best Practices in Cell and Tissue Biopreservation for Clinical Process Development*

TECHNICAL APPLICATIONS TRACK 1

Willow Room

Daily Quality Assessments Performed by Cell Therapy Laboratory Staff

Chair: Victor Lemas (US)

Speakers:

Diane Kadidlo (US)

Olive Sturtevant (US)

8:45am – 9:00am

Opening Remarks

Grand Ballroom ABC

9:00am – 10:30am

PLENARY SESSION 1 – PRESIDENTIAL PLENARY ON MESENCHYMAL STEM CELLS

Grand Ballroom ABC

Chair: Edwin Horwitz (US)

Speakers:

Darwin Prockop (US) – *Medical Therapies with Adult Stem/Progenitor Cells (MSCs): A Backward Journey from Dramatic Results in Vivo to the Cellular and Molecular Explanations*

Jacques Galipeau (US) – *Mesenchymal Stromal Cells for personalized cell therapy. How mechanistic cell physiology studies can inform the design of clinical trials*

Massimo Dominici (IT) – *Revising Janus Bifrons myth for Cellular Therapies based on Mesenchymal Progenitors*

CME credit hours: 1.5

10:30am – 11:00am

Coffee Break with Exhibits

Metropolitan Ballroom & Foyer, Ballard Room

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 1

Grand Ballroom A

Cell and Gene Therapy/Immunotherapy and Dendritic Cells

Co-Chairs: Hans–Peter Kiem (US) and Catherine Bollard (US)

MGMTP140K GENE–MODIFIED CD34+ CELLS ALLOW FOR INCREASED CHEMOTHERAPY ADMINISTRATION AND EXTENDED SURVIVAL IN POOR–PROGNOSIS GLIOBLASTOMA PATIENTS (ABSTRACT#1)

Speaker: Jennifer Adair (US), *Young Investigator Award Recipient*

A SINGLE INFUSION OF ZINC FINGER NUCLEASE (ZFN) CCR5 MODIFIED AUTOLOGOUS CD4 T–CELLS (SB–728–T) CORRELATES WITH INCREASES IN CD4 COUNTS AND EFFECTS ON VIRAL LOAD (VL) IN AVIREMIC HIV–INFECTED SUBJECTS (ABSTRACT #2)

Speaker: Bruce Levine (US)

CATS1 STUDY: IMMUNOMONITORING AND CLINICAL RESULTS OF ANTIGEN–SPECIFIC T REGULATORY (TREG) CELL THERAPY FOR CROHN’S DISEASE (CD) (ABSTRACT #3)

Speaker: Nathalie Clerget–Chossat (FR)

COMBINATION IMMUNOTHERAPY AFTER ASCT FOR ADVANCED MYELOMA WITH MAGE–A3/POLY–ICLC IMMUNIZATION FOLLOWED BY TRANSFER OF VACCINE–PRIMED ACTIVATED AUTOLOGOUS T CELLS (ABSTRACT #4)

Speaker: Nicole Aqai (US)

EFFECTIVE PROPHYLAXIS OF CMV DISEASE IN RECIPIENTS OF ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTS USING ADOPTIVE T CELL TRANSFER – LONG TERM FOLLOW-UP OF 50 PATIENTS (ABSTRACT #5)

Speaker: Emily Blyth (AU)



WEDNESDAY JUNE 6, 2012

ORAL ABSTRACT PRESENTATIONS 2
 Translational Process Development

Grand Ballroom B

Chair: Jon Rowley (US)

PROCESS SCALE-UP AND TRANSITION FROM AUTOLOGOUS TO ALLOGENEIC MANUFACTURING OF CARDIOSPHERE-DERIVED STEM CELLS (ABSTRACT #6)

Speaker: Michelle Kreke (US), *Young Investigator Award Recipient*

THE CRYO-IMAGING SOLUTION TO "WHERE DID MY CELLS GO" (ABSTRACT #7)

Speaker: David Wilson (US)

NAVIGATING THE FIRST-IN-HUMAN IMPLANTABLE POLYMER-DERIVED TUMOR VACCINES INTO A CLINICAL TRIAL (ABSTRACT # 8)

Speaker: Heather Daley (US), *Tech Travel Award Recipient*

DEVELOPMENT OF AN ANGIOGENIC POTENCY ASSAY FOR CLINICAL GRADE STEM CELL PRODUCTION (ABSTRACT #9)

Speaker: Anthony Ting (US)

DEVELOPING LARGE SCALE CELL MANUFACTURING PROCESSES: THE IMPACT ON CELL QUALITY ATTRIBUTES AND COST OF GOODS (ABSTRACT #10)

Speaker: Hemanthram Varadaraju (US)

ORAL ABSTRACT PRESENTATIONS 3
 Cardiovascular Repair and Regeneration/Nervous System Repair

Grand Ballroom C

Co-Chairs: Warren Sherman (US) and Josef Priller (DE)

A PHASE I/II STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS EX VIVO CULTURED ADULT ALLOGENEIC MESENCHYMAL STEM CELLS IN PATIENTS WITH ST ELEVATED ACUTE MYOCARDIAL INFARCTION (STEMI) (ABSTRACT #12)

Speaker: Pawan Gupta (IN)

IRS-BASED LENTIVIRUS CO-EXPRESSING TGFB1 AND FGF2 IMPROVES CELL SURVIVAL AND ANGIOGENESIS IN BONE MARROW DERIVED-MESENCHYMAL STEM CELLS (ABSTRACT #13)

Speaker: Manuela Mura (IT)

A NEW ROLE FOR MENINGES AS A NICHE FOR STEM/PRECURSOR CELLS WITH NEURAL DIFFERENTIATION POTENTIAL DURING DEVELOPMENT UP TO ADULTHOOD (ABSTRACT #14)

Speaker: Mauro Krampera (IT)

SAFETY AND EFFICACY OF INTRACORONARY INFUSION OF ALLOGENEIC CARDIOSPHERE-DERIVED STEM CELLS IN A PIG MODEL OF MYOCARDIAL INFARCTION (ABSTRACT #11)

Speaker: Michelle Kreke (US)

COMPARISON OF HUMAN SCHWANN CELL PROLIFERATION RATES IN CULTURE FROM ORGAN DONOR AND CADAVERIC NERVES (ABSTRACT #15)

Speaker: James Guest (US)

STRATEGIES FOR COMMERCIALIZATION TRACK 2

Grand Ballroom D

Biologics in Personalized Medicine- What are the Development Options beyond Phase 2?

Co-Chairs: Shirley Bartido (US) and David DiGiusto (US)

Speakers:

Renier Brentjens (US) – *Clinical translation of an adoptive therapeutic approach to Cancer: Obstacles from the perspective of an academic investigator*

Martin Schroeder (US) – *Attracting Partners to Help Commercialize Cell Therapy Products*

Michael Zdanowski (US) – *HEMACORD™: The First FDA Approved Allogeneic (Cord Blood Derived) Stem Cell Product A Case Study: From Research to IND to BLA*

Panelists:

For GE: Jiwen Zhang (US) and Firman Ghouze (US)

For CellGenix: Felicia Rosenthal (DE)

For Lonza: Kim Warren (US)

11:00am – 12:15pm

12:15pm – 1:45pm

Lunch with Exhibits

Metropolitan Ballroom & Foyer, Ballard Room



12:30pm – 1:30pm	Corporate Tutorial Hosted by BioLife Solutions <i>(Refer to Corporate Guide for details)</i>	Grand Ballroom A
	Corporate Tutorial Hosted by Title21 Software <i>(Refer to Corporate Guide for details)</i>	Grand Ballroom B
	Corporate Tutorial Hosted by EMD Millipore <i>(Refer to Corporate Guide for details)</i>	Grand Ballroom C
	Technologists Networking Session Chair: Lizette Caballero (US) OPEN TO ALL ATTENDEES	Willow Room
1:45pm – 3:15pm	PLENARY SESSION 2 – CARDIOVASCULAR CELL THERAPY Chair: Michael Laflamme (US) Speakers: Rachel Smith (US) – <i>Autologous and Allogeneic Cardiosphere-Derived Cells for Heart Regeneration</i> April Stempien-Otero (US) – <i>Understanding Mechanisms of Cell Based Therapy in the Human Heart</i> Wolfram Zimmermann (DE) – <i>Therapeutic Heart Muscle from Oocytes</i> Michael Laflamme (US) – <i>Electromechanical Integration and Arrhythmogenic Risk of Human Embryonic Stem Cell-Derived Cardiomyocyte Transplantation</i>	Grand Ballroom ABC CME credit hours: 1
	TECHNICAL APPLICATIONS TRACK 2 Roundtable Debate: Pros and Cons in the Cellular Therapy Field Topic #1: Should closed systems and/or classified facilities be required for processing all cell therapy products? Topic #2: Should donors of HPC or other cell therapy products be financially compensated? Chair: Lizette Caballero (US) Moderators: Paul Eldridge (US), Ann Wilson (US), Martin Hildebrandt (DE), Karen Snow (US), Lynn O'Donnell (US), Michael Boo (US), Lizette Caballero (US), Renee Smilee (US)	Willow Room
3:15pm – 3:30pm	Coffee Break with Exhibits	Metropolitan Ballroom & Foyer, Ballard Room
3:30pm – 5:00pm	WORKSHOP 1 ISCT/USP Joint Session: Ancillary materials Co-Chairs: Elizabeth J. Read (US) and Fouad Atouf (US) Speakers: Elizabeth J. Read (US) – <i>Ancillary Materials: Definitions, Regulatory Framework, and USP's Risk-Tiered Approach</i> Nicole Provost (US) – <i>Ancillary Materials in Cell Therapy Product Development</i> Felicia Rosenthal (DE) – <i>Cytokines and Growth Factor for Ex vivo Cell Culture</i>	Grand Ballroom A
	WORKSHOP 2 Induced Cells for Neurological Disorders Chair: Josef Priller (DE) Speakers: Josef Priller (DE) – <i>Induced stem cells in research and therapy of neuropsychiatric disorders</i> Philip Horner (US) – <i>Neural stem cells derived from human iPS improve forelimb recovery following spinal cord injury</i> Philip Schwartz (US) – <i>An approach to immune-matched neurotherapy in pediatric neurodegenerative diseases</i>	Grand Ballroom B
	WORKSHOP 3 Expansion of Cord Blood Chair: Colleen Delaney (US) Speakers: Elizabeth Cszaszar (CA) – <i>Harnessing hematopoietic stem cell self-renewal to enable therapies</i> Elizabeth J. Shpall (US) – <i>Graft Engineering: The future of cord blood transplantation</i> Colleen Delaney (US) – <i>Enhancing myeloid recovery after cord blood transplantation by infusion of cord blood stem/progenitor cells expanded in the presence of Notch ligand</i>	Grand Ballroom C



WEDNESDAY JUNE 6, 2012

3:30pm – 5:00pm

STRATEGIES FOR COMMERCIALIZATION TRACK 3

Scalable Technologies for Phase 3 and Cell Therapy Commercial Products

Co-Chairs: Frida Grynspan (IL) and Steve Oh (SG)

Speakers:

Jaeseung Lim (KR) – *The autologous T cell therapy product in Korea*

Jef Pinxteren (BE) – *Extensive quality control of MultiStem® cells isolated and expanded using the on the Quantum CES*

Steve Oh (SG) – *Stem cell bioprocessing: Superior cell expansion and differentiation on microcarriers*

Lye Theng Lock (US) – *Scalable kSep Process for Therapeutic Cell Concentration and Residual Clearance*

Grand Ballroom D

TECHNICAL APPLICATIONS TRACK 3

Optimizing Clinical Outcomes of Cord Blood Transplantation through Enhanced Selection, Testing and Preparation

Chair: Donna Regan (US)

Speakers:

Joanne Kurtzberg (US) – *How does cord blood potency impact clinical outcomes after cord blood transplantation?*

Donna Wall (CA) – *Preparation of cord blood for infusion: wash, no wash, or somewhere in between*

Karen Ballen (US) – *Optimal Cord Blood Unit Selection: Beyond Cell Dose*

Willow Room

5:00pm – 6:00pm

POSTER SESSION 1

Ravenna Room

THURSDAY JUNE 7, 2012

7:00am – 4:00pm

Registration Open

Grand Ballroom Foyer

Corporate Tutorial Hosted by CellGenix GmbH and AFC (Refer to Corporate Guide for details)

Grand Ballroom A

TECHNICAL SESSION 3

Cell Engineering

Chair: David DiGiusto (US)

Speakers:

David DiGiusto (US) – *Zinc Finger Nuclease mediated genomic editing of CCR5 in human hematopoietic stem and progenitor cells for clinical application in HIV gene therapy*

Christine Brown (US) – *Phenotypic and Functional Attributes of Lentivirus Modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale*

Grand Ballroom B

7:30am – 8:30am

TECHNICAL SESSION 4

Funding for Early Stage Cell Based Therapies

Chair: Ellen Feigal (US)

Speakers:

Ellen Feigal (US) – *Advancing Stem Cell Science Towards Therapies for Patients: CIRM's Initiatives and Funding Opportunities*

Lis Welniak (US) – *NHLBI Update on Funding and Resources for Studies in Cellular Therapy*

Grand Ballroom C

STRATEGIES FOR COMMERCIALIZATION TRACK 4

Cell Characterization Assays

Co-Chairs: Wouter Van't Hof (US) and Timothy Fong (US)

Speakers:

Wouter Van't Hof (US) – *Potency assay development for MultiStem, a stromal cell therapy product*

Amy Putnam (US) – *Bench to Bedside: Successful Implementation of a Phase I Clinical Trial from an Academic Standpoint*

Grand Ballroom D



7:30am – 8:30am

TECHNICAL APPLICATIONS TRACK 4

Willow Room

Preparing Agreements for Contract Services Inside and Outside Your Institution

Chair: Ann Wilson (US)

Speakers:

Victor Lemas (US) – *Why you need to care about Internal Agreements?*
Liz Cardwell (US) – *Great Expectations: External Supplier Agreements*

8:45am – 10:15am

PLENARY SESSION 3 – STEM CELLS FOR GENE THERAPY

Grand Ballroom ABC

Chair: Hans-Peter Kiem (US)

Speakers:

Christoph Klein (DE) – *Hematopoietic stem cell gene therapy for Wiskott–Aldrich Syndrome – efficacy and risks*
Nathalie Cartier (FR) – *Hematopoietic stem cell gene therapy for X-linked Adrenoleukodystrophy*
Andrew Scharenberg (US) – *Cell engineering with rare cleaving nucleases: technology landscape and applications*

CME credit hours: 1.5

TECHNICAL APPLICATIONS TRACK 5

Willow Room

Translating Science from Bench to Bedside with Real Case Scenarios

Chair: Renee Smilee (US)

Speakers:

Ian Nicoud (US) – *Part 1: From model to manufacture – creating a clinical product from research findings*
Jason Carstens (US) – *Part 2: Process Development and Design for Manufacturing*
Tory Lake (US) – *Part 3: Navigating the regulatory path to clinical application*
Colleen Delaney (US) – *Part 4: Realizing the goal – clinical outcomes and future directions*

10:15am – 10:45am

Coffee Break with Exhibits

Metropolitan Ballroom & Foyer, Ballard Room

10:45am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 4

Grand Ballroom A

Basic Biology of Non–Hematopoietic Stem Cells/Non–Hematopoietic Stem Cells Towards Clinics

Chair: Luc Sensebé (FR)

HUMAN MESENCHYMAL STEM CELLS EXPRESS PROTEINS BELONGING TO OR RELATED TO THE IL1 FAMILY THAT CONTRIBUTE TO THEIR ANTI-INFLAMMATORY ACTIVITY (ABSTRACT #17)

Speaker: Siddaraju Boregowda (US)

REGULATING HUMAN MESENCHYMAL STEM CELLS FOR OSTEOGENIC TISSUE REPAIR BY P63 AND P38 ISOFORMS (ABSTRACT #18)

Speaker: Guy Howard (US)

MSC FUNCTIONALITY AND ROBUSTNESS OF THE MSC EXPANSION PROCESS ARE CRITICALLY DEPENDENT ON TISSUE SOURCE AND EXPANSION CONDITIONS (ABSTRACT #19)

Speaker: Helene Roelofs (NL)

MESENCHYMAL STROMAL CELL THERAPY FOR REFRACTORY CROHN'S DISEASE (ABSTRACT #20)

Speaker: Janice Fogarty (AU), *Tech Travel Award Recipient*

MOBILIZATION OF MESENCHYMAL STEM CELLS FROM THE BONE MARROW TO PERIPHERAL BLOOD (ABSTRACT #21)

Speaker: Ian McNiece (US)

PROSPECTIVELY ISOLATED SCAVENGING BONE-MARROW SINUSOIDAL ENDOTHELIAL CELLS HOME TO, AND REVASCULARIZE THE BONE MARROW OF TRANSPLANTED ABLATED RECIPIENTS (ABSTRACT #16)

Speaker: Susie Nilsson (AU)



THURSDAY JUNE 7, 2012

ORAL ABSTRACT PRESENTATIONS 5
Hematopoietic Stem Cells

Grand Ballroom B

Co-Chairs: Susie Nilsson (AU) and Shelly Heimfeld (US)

OPTIMIZING MEGAKARYOCYTE POLYPLIIDIZATION INCREASES PLATELET RELEASE IN CULTURE (ABSTRACT #22)

Speaker: Mauro Avanzi (US)

HEMATOPOIETIC STEM CELLS AND MEGAKARYOCYTE PROGENITORS AND THEIR SUBSETS DIFFER IN NORMAL AND MEYELOPROLIFERATIVE DISEASE STATES (ABSTRACT #23)

Speaker: Varda Deutsch (IL)

ALDH^{BR} CONTENT OF SEGMENTS FROM BANKED CORD BLOODS PREDICTS ENGRAFTMENT AFTER CORD BLOOD TRANSPLANTATION (ABSTRACT #24)

Speaker: Kevin Shoulars (US)

NANOLITER DROPLET VITRIFICATION FOR BLOOD AND STEM CELL CRYOPRESERVATION (ABSTRACT #25)

Speaker: Claudia Zylberberg (US)

LUMINOMETRIC DETERMINATION OF PROGENITOR CELL FUNCTION IN CRYOPRESERVED PERIPHERAL BLOOD STEM CELL HARVESTS (ABSTRACT #26)

Speaker: Beate Wagner (DE)

WHAT CLINICAL CHARACTERISTICS OF AFRICAN AMERICAN MOTHERS AND BABIES FAVORABLY INFLUENCE CORD BLOOD POTENCY? DEFINING PARAMETERS THAT CAN GUIDE PUBLIC CORD BLOOD COLLECTION (ABSTRACT #27)

Speaker: Kristin Page (US)

10:45am – 12:15pm

STRATEGIES FOR COMMERCIALIZATION TRACK 5

Grand Ballroom D

Key Considerations for Cell Therapy Pivotal Trials and Beyond

Chair: Darin Weber (US)

Speakers:

Lynn Allen-Hoffmann (US) – *Great Expectations: Readyng your Technology for Regulatory Assessment*

Paul Williamson (US) – *Development of Cell-based Therapies in a Large Organization: Orchestrate for Success*

Darin Weber (US) – *Insights and Considerations in Preparing for Phase 3 Cell Therapy Studies*

TECHNICAL APPLICATIONS TRACK 6

Willow Room

Regulations Around the World

Chair: Karen Edward (US)

Speakers:

Martin Bleasdale (AU) – *Regulations around the world – an Australian perspective*

Mark Lowdell (UK) – *Regulation of ATMP trials in the EU: is it breaking the 'virtuous circle'?*

Halvard Bönig (DE) – *Academia and advanced cell therapy: A German Perspective*

Jaeseung Lim (KR) – *The regulation and the development of cell therapy products in Korea*

12:15pm – 1:45pm

Lunch with Exhibits

Metropolitan Ballroom & Foyer, Ballard Room

12:30pm – 1:30pm

Corporate Tutorial Hosted by ATMI LifeSciences (Refer to Corporate Guide for details)

Grand Ballroom A

Corporate Tutorial Hosted by Charter Medical (Refer to Corporate Guide for details)

Grand Ballroom B

Corporate Tutorial Hosted by Panasonic Healthcare Company of North America (Refer to Corporate Guide for details)

Grand Ballroom C

Corporate Tutorial Hosted by STEMCELL Technologies (Refer to Corporate Guide for details)

Grand Ballroom D



<p>1:45pm – 3:15pm</p>	<p>PLENARY SESSION 4 – REGENERATIVE MEDICINE AND POSITIONING FOR COMMERCIAL SUCCESS Co-Chairs: Kurt Gunter (US) and Tracey Lodie (US) <i>Grand Ballroom ABC</i> Speakers: John McMannis (US) – <i>“Off the Shelf” Stem Cell Products for Regenerative Medicine</i> Mark Frolich (US) – <i>Commercialization of Sipuleucel-T, the First FDA Approved Autologous Cellular Immunotherapy for Cancer</i> Gil Beyen (BE) – <i>Lessons from the commercial roll out of ChondroCelect in Europe</i></p>
<p>3:15pm – 3:30pm</p>	<p>TECHNICAL APPLICATIONS TRACK 7 <i>Willow Room</i> New perspectives in cell selection Chair: Martin Hildebrandt (DE) Speakers: Stanley Riddell (US) – <i>Selecting defined subsets of T cells for genetic modification and cell therapy</i> Caroline Keever-Taylor (US) – <i>Cell enrichment and depletion using the CliniMACS device: Factors affecting outcome</i> Dirk Busch (DE) – <i>Reversible cell labeling technologies for clinical cell processing and purification</i></p>
	<p>Coffee Break with Exhibits <i>Metropolitan Ballroom & Foyer, Ballard Room</i></p>
<p>3:30pm – 5:00pm</p>	<p>WORKSHOP 4 <i>Grand Ballroom A</i> ISCT Reimbursement Roundtable Highlights Chair: Richard Maziarz (US) Speakers: Robert Deans (US) Richard Maziarz (US)</p>
	<p>WORKSHOP 5 <i>Grand Ballroom B</i> Platelet and Erythrocyte Production – Progress in Manufacturing and Drug Delivery Chair: Luc Douay (FR) Speakers: Luc Douay (FR) – <i>In vitro red blood cell production: state of the art</i> Jo Anna Reems (US) – <i>In vitro platelet production: myth or future reality</i> Yan Godfrin (FR) – <i>Red Blood Cells for a New Drug Formulation</i></p>
	<p>STRATEGIES FOR COMMERCIALIZATION TRACK 6 <i>Grand Ballroom D</i> Sourcing Biologic Materials and Managing Supply Chains – Quality Considerations Chair: Scott Burger (US) Speakers: Dominic Clarke (US) – <i>Managing Particulates in Cellular Therapy</i> Gaytha McPherson (US) – <i>Optimizing Apheresis Cellular Collections</i> Emmanuelle Charton (Council of Europe) – <i>How the European Pharmacopoeia can contribute to the quality of raw materials for the production of cellular and gene transfer products</i> Hermann Bohnenkamp (DE) – <i>Controlled, standardized cytokines and cell culture media for manufacturing Advanced Therapies</i></p>
	<p>TECHNICAL APPLICATIONS TRACK 8 <i>Willow Room</i> Challenges New Customers Present to the CT Lab Chair: Lynn O’Donnell (US) Speakers: Carolyn Lutzko (US) – <i>The Art and Science of Translating a Cell Therapy from Mouse to Man</i> Tom Leemhuis (US) – <i>Teaching surgeons how to do cell therapy</i> Deborah Griffin (US) – <i>Practical methods for regulatory compliance and documentation of new protocol implementation for the CT Lab</i></p>
<p>5:00pm – 6:00pm</p>	<p>POSTER SESSION 2 <i>Ravenna Room</i></p>
<p>7:30pm – midnight</p>	<p>GALA – TICKETED EVENT <i>Experience Music Project (EMP) Museum</i></p>



FRIDAY JUNE 8, 2012

7:00am – 3:00pm

Registration Open

Grand Ballroom Foyer

TECHNICAL SESSION 5

Ex-vivo and in-vivo graft engineering

Chair: Stephan Mielke (DE)

Speakers:

Stephan Mielke (DE) – *TH9402-based, ex vivo allodepletion to improve matched and mismatched transplants*

Catherine Bollard (US) – *Ex vivo expanded multi-virus specific T cells to reduce infectious complications after allogeneic stem cell transplantation*

Paul O'Donnell (US) – *Cyclophosphamide-Induced Tolerance in BMT*

Grand Ballroom B

TECHNICAL SESSION 6

TPP Workshop

Chair: Ellen Feigal (US)

Speakers:

Ellen Feigal (US) – *Target Product Profile – Key Guide in Product Development*

Wilson Bryan (US) – *Target Product Profile – A Regulatory Perspective*

Grand Ballroom C

7:30am – 8:30am

TECHNICAL SESSION 7

Freezing of Living Cells for Cellular Therapy: A Challenge for Biomedical Scientists

Chair and Speaker: Dayong Gao (US)

Grand Ballroom A

STRATEGIES FOR COMMERCIALIZATION TRACK 7

Strategic Partnering and Technology Transfer

Chair: Dean Tozer (US)

Speakers:

Dean Tozer (US) – *Creating value in today's Regenerative Medicine environment*

Kenneth L. Harris (US) – *Increase the Success of CT Clinical Trials: An Affordable High Quality Model*

Timothy Davidson (US) – *Global Strategy for Successful Cell Therapy Products*

Grand Ballroom D

TECHNICAL APPLICATIONS TRACK 9

Point of Care Devices in Cell Therapy

Chair: Dominic Wall (AU)

Speakers:

Dominic Wall (AU) – *New Technologies in Cell Therapy Manufacturing*

David James (AU) – *Developing and implementing new technology for cell therapy*

Willow Room

8:45am – 10:15am

PLENARY SESSION 5 – REGENERATION REVISITED

Chair: John Rasko (AU)

Speakers:

Andras Nagy (CA) – *Toward understanding the process of somatic cell reprogramming to pluripotency*

Shahin Rafii (US) – *Vascular niche-derived angiocrine factors initiate and sustain organ regeneration*

Grand Ballroom ABC

CME credit hours: 1.5

TECHNICAL APPLICATIONS TRACK 10

Lean Process for Processing Laboratories: When can we use it with examples

Chair: Karen Foster (US)

Speakers:

Brent McKinnon (US) – *ViaCord Cord Blood Processing – Matching Unit Cycle Time to Take Time*

Jennifer Glejf (US) – *Getting LEAN in the Human Cell Therapy Lab: How Applying LEAN Principals to One Area of the Lab Caught on Like Wildfire*

Willow Room

10:15am – 10:45am

Coffee Break with Exhibits

Metropolitan Ballroom & Foyer, Ballard Room



	<p>ORAL ABSTRACT PRESENTATIONS 6 <i>Grand Ballroom A</i> Lab Practices/Legal and Regulatory Affairs</p> <p>Co-Chairs: Deborah Lamontagne (US) and Karen Nichols (US)</p> <p>POST THAW CD34 RECOVERY AND VIABILITY OF HEMATOPOIETIC PROGENITOR CELLS IS A VALUABLE CLINICAL TOOL IN AUTOLOGOUS BLOOD AND MARROW TRANSPLANTS (ABSTRACT #29) Speaker: Susan Berrigan (CA)</p> <p>STABILITY OF THAWED HEMATOPOIETIC PROGENITOR CELLS (HPC) IN DIMETHYL SULFOXIDE (DMSO) IN FILTERED AND UNFILTERED PRODUCTS (ABSTRACT #28) Speaker: Mehraboon Irani (US)</p> <p>ESTABLISHING THE NECESSARY DATA TO MODEL THE FUTURE RESOURCE REQUIREMENTS AND PREDICTED HEALTHCARE TARGETS FOR CELL THERAPY AS PART OF ROUTINE CLINICAL PRACTICE (ABSTRACT #30) Speaker: Emily Culme-Seymour (UK)</p> <p>REGULATORY IMPLICATIONS OF ALLOGENEIC CELL BANKING STRATEGY (ABSTRACT #31) Speaker: Christopher Bravery (UK)</p>
10:45am – 11:45pm	<p>ORAL ABSTRACT PRESENTATIONS 7 <i>Grand Ballroom B</i> Regenerative Medicine</p> <p>Chair: Shelly Heimfeld (US)</p> <p>SYSTEMIC HUMAN ORBITAL FAT-DERIVED STEM CELL TRANSPLANTATION AMELIORATES ACUTE INFLAMMATION IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY (ABSTRACT #32) Speaker: Jennifer Ho (TW)</p> <p>A NEO-KIDNEY AUGMENT PRODUCT FOR KIDNEY REGENERATION IN A LARGE ANIMAL MODEL OF CHRONIC KIDNEY DISEASE (ABSTRACT #33) Speaker: Deepak Jain (US)</p> <p>CONTRIBUTION OF HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL CELLS IN VASCULAR REGENERATION OF BLEOMYCIN-INDUCED SCLERODERMA MOUSE MODEL (ABSTRACT #34) Speaker: Nasser Aghdami (IR), <i>Young Investigator Award Recipient</i></p> <p>STANDARDIZED QUALITY CONTROL AND CELL EQUIVALENCY FOR XENO-FREE MULTISTEM®, AN ADHERENT STEM CELL THERAPEUTIC (ABSTRACT #35) Speaker: Annelies Bogaerts (BE)</p>
	<p>TECHNICAL APPLICATIONS TRACK 11 – ENDS AT 12:00PM <i>Willow Room</i> Selling Cellular Therapies to consumers: The good, the bad and the ugly Chair: Bruce Levine (US) Speakers: Aaron Levine (US) – <i>Assessing patients' experiences with unproven stem cell interventions</i> Timothy Caulfield (CA) – <i>The Big Sell: The Marketing of Unproven Therapies</i></p>
11:45pm – 1:15pm	<p>Lunch with Exhibits <i>Metropolitan Ballroom & Foyer, Ballard Room</i></p>
12:00pm – 1:00pm	<p>ANNUAL GENERAL MEETING (AGM) <i>Grand Ballroom B</i> All ISCT Members invited to attend</p>
1:15pm – 2:45pm	<p>WORKSHOP 6 <i>Grand Ballroom A</i> ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US) Speakers: Les Silberstein (US) – <i>Objectives of the PACT program</i> Myriam Armant (US) – <i>Examples of PACT II Enabled Translational and Clinical Applications at CHCT</i> David McKenna (US) – <i>Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience</i> Adrian Gee (US) – <i>PACT-Supported Development of Virus-Directed T Cell Therapy</i> Larry Couture (US) – <i>Process development for scalable cardiomyocyte differentiation from hES cells</i></p>



FRIDAY JUNE 8, 2012

	<p>WORKSHOP 7 MSC Production and Clinical Uses: Impact of Production Methods on Potency and Safety Co-Chairs: Luc Sensebé (FR) and Mauro Krampera (IT) Speakers: Hillard Lazarus (US) – <i>Novel uses for MSCs and MAPCs</i> David Stroncek (US) – <i>BM MSCs Production and Assessment for Clinical Applications</i> Luc Sensebé (FR) – <i>MSCs from Safety Concerns to Controls</i></p>	<p><i>Grand Ballroom C</i></p>
<p>1:15pm – 2:45pm</p>	<p>STRATEGIES FOR COMMERCIALIZATION TRACK 8 Tissue Engineering in 2012: Lost in Commercial Translation? Chair: Sharon Presnell (US) Speakers: Sharon Presnell (US) – <i>Capturing the value from science: Translating promising research into a tangible asset</i> Dean Tozer (US) – <i>Ushering an innovative regenerative medicine product from development to the market</i> Timothy Fong (US) – <i>From Idea to Product: The pathway from academic innovation to a commercial manufacturing process</i></p>	<p><i>Grand Ballroom D</i></p>
	<p>TECHNICAL APPLICATIONS TRACK 12 Strenuous Standards: Savvy Solutions Chair: Lynn O'Donnell (US) Speakers: Douglas Padley (US) – <i>The Search for Balance: Control vs Creativity in the Development and Implementation of Novel Cellular Therapy Product Trials</i> Jessica Carmen (US) – <i>Molecular Trilineage Assay for Identity Testing of hMSCs</i> John Duguid (US) – <i>Validation of Rapid Mycoplasma Testing using Real-Time PCR</i> Michele Cottler-Fox (US) – <i>Garbage in, garbage out: a predictive formula to improve efficiency and quality for HPC collection and processing facilities</i></p>	<p><i>Willow Room</i></p>
<p>2:45pm – 2:50pm</p>	<p>Break</p>	
<p>2:50pm – 2:55pm</p>	<p>ANNOUNCEMENT: BEST POSTER AWARD/BEST ORAL ABSTRACT AWARD RECIPIENTS</p>	
<p>2:55pm – 4:25pm</p>	<p>PLENARY SESSION 6 – IMMUNOTHERAPY AND T-CELLS Chair: Philip Greenberg (US) Speakers: Philip Greenberg (US) – <i>T cells vs. tumors: Preparing T cells for the kill</i> Michael Jensen (US) – <i>Enhancing the IQ of CAR-modified T Cells</i> Renier Brentjens (US) – <i>Chimeric antigen receptor (CAR) modified T cells as a novel approach to immuno-therapy of B cell malignancies</i></p>	<p><i>Grand Ballroom ABC</i> CME credit hours: 1.5</p>
	<p>TECHNICAL APPLICATIONS TRACK 13 ISBT Labeling Implementation – Presentation of Real Scenarios Co-Chairs: Lizette Caballero (US) and Leigh Sims Poston (US) Speakers: Kathy Watkins (US) – <i>ISBT Labeling: One Small Lab's Implementation Experience</i> Mary McLeod (US) – <i>Developing an ISBT 128 plan for Cell Therapy Labs and Apheresis Collection Facilities</i></p>	<p><i>Willow Room</i></p>